[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitamin-d-insufficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitamin-d-insufficiency":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645392","an-investigation-of-the-effect-of-vitamin-d-level-during-frozen-embryo-transfer-fet-in-ivf-and-pregnancy-outcomes-100645392",false,"NCT07681115","An Investigation of the Effect of Vitamin D Level During Frozen Embryo Transfer (FET) in IVF and Pregnancy Outcomes","Vitamin D Levels and Pregnancy Outcomes Following Frozen Embryo Transfer (FET) in the UAE","VitD in FET","Inclusion:\n\n* Women undergoing frozen embryo transfer (FET) at Fakih IVF.\n* Age between 18 and 40 years.\n* Body mass index (BMI) between 18 and 40 kg\u002Fm².\n* Patients who had serum vitamin D levels assessed within three months prior to FET\n* Supplementation with Vitamin D if deficient \\\u003C 30 ng\u002FmL (75 nmol\u002FL).\n\nExclusion:\n\n* Age below 18 years or above 40 years.\n* BMI below 18 kg\u002Fm² or above 40 kg\u002Fm².\n* Patients who did not have vitamin D levels measured within three months prior to FET.\n* Patients who were found to have low vitamin D levels but did not receive supplementation.\n* Patients with recurrent implantation failure (RIF).\n* Patients with known uterine factors affecting implantation (e.g., congenital uterine anomalies, intrauterine adhesions, submucosal fibroids).\n* Patients with significant medical comorbidities that may affect pregnancy outcomes.","FEMALE","18 Years","40 Years",{"count":21,"type":22},126,"ESTIMATED","OBSERVATIONAL","Vitamin D is best known for keeping our bones healthy, but growing research suggests it may also play a role in fertility. Many IVF clinics now routinely check vitamin D levels and prescribe supplements before treatment, but the science is still unclear on whether this actually improves the chances of pregnancy.\n\nOur study, based in the UAE, aims to find out whether a woman's vitamin D level on the day of her frozen embryo transfer (FET) makes a difference to whether she becomes pregnant and delivers a baby. The UAE is an ideal setting for this research, as vitamin D deficiency is particularly common in the region. The findings could shape how fertility clinics screen and treat women seeking fertility treatment in the future.",[26,27],"Vitamin D Insufficiency","In Vitro Fertilization and Embryo Transfer",[29,30],"frozen embryo transfer cycle","Vitamin D","RECRUITING","2026-06-26",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2026-06-01",{"date":39,"type":22},"2027-08",{"name":41,"class":42},"Fakih IVF Fertility Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100333455","phase-4-vitamin-d-homeostasis-in-sarcoidosis-100333455","NCT03621553","Vitamin D Homeostasis in Sarcoidosis","Inclusion Criteria:\n\n* Stable medical condition defined as no hospitalization or emergency room visit in the previous 3 months\n* No evidence of active pulmonary or systemic infection\n* No other active inflammatory disease,\n* No active malignancy.\n* Normal serum ionized calcium level\n\nExclusion Criteria:\n\n* Hospitalization or emergency room visit in the previous 3 months\n* Evidence of active pulmonary or systemic infection\n* Evidence of active other inflammatory disease\n* Evidence of active malignancy\n* Elevated serum ionized calcium level","ALL","21 Years",{"count":53,"type":22},90,"INTERVENTIONAL",[56],"PHASE4","This study evaluates the relationship between vitamin-D status and severity of sarcoidosis, and the effects of vitamin-D repletion in vitamin-D insufficient patients with sarcoidosis. Half the patients with sarcoidosis who are vitamin-D insufficient will receive standard vitamin-D supplementation via standard regimen while the other half will receive a placebo. Sarcoidosis patients who are vitamin-D sufficient will also act as controls.",[59,26],"Sarcoidosis","2025-12-30",{"date":62,"type":35},"2026-01-02",{"date":64,"type":35},"2010-07-01",{"date":66,"type":22},"2026-12-30",{"name":68,"class":42},"University of Texas Southwestern Medical Center",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":50,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":54,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":106},"100576880","25oh-vitamin-d-and-its-association-with-structural-and-functional-parameters-in-hospitalized-patients-with-neurological-diseases-100576880","NCT06791044","25(OH)-Vitamin D and Its Association With Structural and Functional Parameters in Hospitalized Patients With Neurological Diseases","25(OH)-Vitamin D and Its Association With Bone Density, Body Composition, Strength, Walking Speed, Physical Performance and Pain in Hospitalized Individuals With Neurological Disorders","NeuroVitD","Inclusion Criteria:\n\n* populations with neurological disorders\n* healthy volunteers (controls)\n\nExclusion Criteria:\n\n* The subject is excluded if they:\n\n  * are legally or mentally incapable of comprehending and consenting to participate in the study\n  * have a history of or exhibit indicators of metabolic bone disease, including the following: Hypoparathyroidism, primary hyperparathyroidism, recent hyperthyroidism (within the last six months), Paget's disease of bone;\n  * grade 3 or 4 pressure ulcers present;\n  * has undergone treatment with pharmacological agents influencing bone metabolism prior to the initial bone density assessment, including the following: bisphosphonates in the year prior to the bone density assessment ; parathyroid hormone in the year prior to the research ; estrogens, selective estrogen receptor modulators (SERMs), tibolone, or anabolic steroids within the preceding six months.\n  * Thyroid drugs are permissible only if the dosage has remained consistent for the preceding six weeks and TSH levels are within the normal range.\n  * Corticosteroid medication exceeding 7.5 mg of prednisone orally per day for a duration exceeding one month within the past six months.\n  * Immunosuppressant therapy within the past year;\n  * Vitamin A therapy above 10,000 IU per day or Vitamin D exceeding 5,000 IU per day.\n  * Participants are prohibited from consuming additional vitamin D supplements exceeding 400 IU per day or traveling to regions with heightened sunshine exposure during the trial.",true,"20 Years","85 Years",{"count":81,"type":22},120,[83],"NA","The NeuroVitD study aims to assess vitamin D levels in hospitalized cohorts with neurological disorders resulting in motor disabilities, providing epidemiological data necessary for guidelines. The primary objective is to assess vitamin D insufficiency in the neurological populations under investigation and secondary to evaluate the impact of vitamin D supplementation on problems associated with structural and functional parameters.\n\nThe NeuroVitD study will be a randomized, cluster, controlled intervention trial lasting 2 years, enrolling 120 individulas, (30 controls), including those with stroke, spinal cord injury, and traumatic brain injury. Comprehensive epidemiological data, including demographic and anthropometric information, will be documented alongside social behaviors such as exercise and smoking. Serum vitamin D levels, bone density, body composition, strength, speed, physical performance and pain will be assessed.\n\nThe study will also evaluate the effects of vitamin D supplementation at two distinct dosages: 50,000 I.U of vitamin D weekly for 8 weeks or 25,000 I.U of vitamin D for 4 weeks followed by 10,000 I.U of vitamin D drops weekly for an additional 4 weeks. Calcium, parathyroid hormone, and phosphorus levels will be assessed to examine the impact of vitamin D administration on additional biochemical markers.\n\nThe findings will encompass vitamin D levels, bone density, body composition, strength, walking speed, physical performance and pain. The impact of vitamin D supplementation on various biochemical parameters will be analyzed, along with gender and group comparisons. Correlations will be established based on participants' residential locations, the administration of vitamin D supplementation, seasonal variations, and associations with specific medications for neurological conditions.",[26],[87,88,89,90,91,92,93,94,95],"25OHvitD","bone density","body composition","strength","pain","sarcopenia","osteoporosis","sarcopenic obesity","rehabilitation","2025-06-03",{"date":98,"type":35},"2025-06-08",{"date":100,"type":35},"2025-06-01",{"date":102,"type":22},"2027-12-31",{"name":104,"class":105},"Dionyssiotis, Yannis, M.D.","INDIV",2]